Iron isomaltoside 1000
- Generic Name
- Iron isomaltoside 1000
- Drug Type
- Small Molecule
- CAS Number
- 1370654-58-2
- Unique Ingredient Identifier
- 3M6325NY1R
- Background
Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.
- Associated Conditions
- Iron Deficiency (ID), Iron Deficiency Anemia (IDA)
Robust Pipeline of 80+ Therapies Advancing for Chronic Kidney Disease Treatment in 2025
• DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern.
• Key late-stage candidates include AstraZeneca's Baxdrostat and Novo Nordisk's Ziltivekimab, targeting different pathways in CKD progression with promising clinical results.
• Multiple novel mechanisms are being explored across all development stages, including aldosterone synthase inhibition, anti-inflammatory approaches, and soluble guanylate cyclase activation, expanding potential treatment options.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath